Lifecore Biomedical Inc. Common Stock (LFCR)

FairStock Score: 15/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look first for a durable business with stable earning power and a conservative balance sheet. Lifecore is a specialized contract manufacturer for sterile injectables—aseptic fill-finish in syringes, vials, and cartridges—which can be a sticky niche, but the numbers show a fragile enterprise. In fiscal 2024, the company earned $12.0M on $128.3M of revenue. By fiscal 2025, revenue was roughly flat at $128.9M, yet net income swung to a loss of $38.7M, or $1.27 per diluted share. The losses continued: in fiscal Q1 2027, the quarter ended 2026-06-30, revenue was $34.2M and net income was -$6.2M, an improvement from the -$15.0M loss in fiscal Q3 2026, the quarter ended 2026-03-31. Still, a business that cannot consistently earn profits is not a moat; it is a question mark. The balance sheet is stretched, with FairStock's debt-to-equity at 9.72 and an Altman Z-Score of -0.43, which points to financial distress. Trailing free cash flow of $4.2M gives a FairStock FCF yield of just 1.7%, hardly enough to cover risk. At the 2026-10-13 close of $6.42, FairStock's P/E is -5.06 and EV/EBITDA is 98.11; those are not Graham-style bargains, they are turnaround options. I would need evidence of sustained revenue growth, durable margins, and debt reduction before calling this a sound value proposition.

In plain English: Lifecore is a contract manufacturer that fills and finishes sterile injectable drugs in syringes, vials, and cartridges. The business looks weak right now: it lost money in fiscal 2025 and in recent quarters, sales have recently slipped, and it carries a lot of debt. At $6.42, the price does not look cheap against those weak profits and limited cash generation; it looks more like a speculative turnaround.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q4 2025 10-Q (period ended 2025-05-25) · FY2025 10-K (period ended 2025-05-25) · FY2024 10-K (period ended 2024-05-26) · FY2023 10-K (period ended 2023-05-28)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer